Refractory anemia (RA) in myelodysplastic syndromes (MDS) are very heterogeneous diseases regarding their morphology, clinical features and survival. We proposed the new designations 'RA with severe dysplasia (RASD)' and 'RA with minimal dysplasia (RAminiD)'. In our criteria, RASD is considered present if a bone marrow (BM) examination shows PseudoPelger-Huet anomalies of mature neutrophils у3% and/or micromegakaryocytes (mMgk) of megakaryocytes у10% in RA patients. RAminiD is defined as RA cases other than RASD. After the reclassification of 58 primary RA patients, the group was composed of 45 RAminiD and 13 RASD patients. The blast percentage in the BM and the frequency of cytogenetic abnormalities observed in the RASD patients were intermediate between those in the RAminiD and RAEB patients. The analysis of survival curves revealed differences among the three groups; the RASD patients had lower survival probabilities than those of the RAminiD group, and significantly higher probabilities than those of the RAEB group. (RAminiD vs RASD, P = 0.06; RASD vs RAEB, P = 0.004.) Our data indicate that in RA patients, RASD is a distinct subset of RA with an unfavorable clinical outcome.
Introduction
Myelodysplastic syndromes (MDS) are acquired clonal stem cell disorders characterized by ineffective hematopoiesis with myelodysplasia 1 and are associated with a high risk of progression to acute leukemias. 2 The diagnosis of MDS requires careful light microscopic examination of the peripheral blood smear, bone marrow aspirate smear and biopsy.
MDS are very heterogeneous diseases regarding their morphology, clinical features and survival. 3 Refractory anemia (RA) and RA with ringed sideroblasts (RARS) are generally classified as low-risk groups in MDS. 4 Rosati et al 5 recently proposed the entity of refractory cytopenia with multilineage dysplasia (RCMD), and reported that the outcome of the RCMD patients was unfavorable. Kuriyama et al 6 reported that Pseudo-Pelger-Huet anomalies and micromegakaryocytes (mMgk) are specific in MDS. In the present study, we chose two distinct dysplastic changes (Pseudo-Pelger-Huet anomalies and mMgk), and propose the new designations 'RA with severe dysplasia (RASD)' and 'RA with minimal dysplasia (RAminiD)'. We investigated the clinical significance of RASD and RAminiD. 
Patients and methods

Patients
A total of 80 consecutive patients with the diagnosis of primary RA and RA with excess of blasts (RAEB) according to the FAB criteria were included in the retrospective analysis. Patients were diagnosed at the Saitama Medical School Hospital between January 1983 and October 1996. Of the patients, 58 were diagnosed as having RA and 22 as having RAEB.
Morphological analysis
Hematological examinations were performed using standard methods (peripheral blood (PB) and bone marrow (BM) Wright-Giemsa stained films). PB and BM differential counts were performed on 100 and 500 cells, respectively. A minimum of 25 megakaryocytes and 200 mature neutrophils were examined in each patient. The evaluation of dysplasia has been used for Rosati's criteria: erythroid dysplasia, megaloblastoid change and/or nuclear budding and/or multiple nuclei у3% or karyorrhexis у5%; granulocytic dysplasia, cytoplasmic hypogranularity and/or hypo-or hypersegmented nuclei у3%; megakaryocytic dysplasia, micromegakaryocytes or multiple, widely separated or single, non-lobated nuclei and a fully mature cytoplasm у10%. 5 In addition, two especially distinct dysplastic changes were chosen (PseudoPelger-Huet anomalies and mMgk), and their morphological abnormalities could be evaluated. In this study, we propose the new designations 'RA with severe dysplasia (RASD)' and 'RA with minimal dysplasia (RAminiD)'. In our criteria, RASD was considered present if the BM examination showed Pseudo-Pelger-Huet anomalies of mature neutrophils у3% and/or mMgk of megakaryocytes у10% in RA patients. RAminiD was defined as RA other than RASD. Each case of RA was reviewed and reclassified according to our criteria and Rosati's criteria (RCMD: RA showing trilineage dysplasia in the BM examination; Rosati's RA: RA showing minimal or absent dysgranulopoiesis and dysmegakaryopoiesis in the BM examination). 5 The morphological analysis was separately evaluated by two hematologists (AM and IJ).
Cytogenetic analysis
Cytogenetic analyses were performed with a trypsin-Giemsa banding technique on BM cells from aspirates. Cells from short-term unstimulated cultures (Ͻ48 h) were examined. Chromosomal abnormalities were identified by the International System for Human Cytogenetic Nomenclature. 
Statistical analysis
The Kaplan-Meier method 8 was used to estimate the probability of overall survival and leukemic transformation. Survival was measured from the date of diagnosis at our hospital or affiliated hospitals until death due to any cause or until the last patient contact, as of October 1997. Leukemic transformation was measured from diagnosis. The analyses of survival curve and leukemic transformation curve were done using the log rank test. 9 Statistical comparisons were performed by use of the nonparametric Mann-Whitney test for continuous data.
Results
The case of each RA patient was reviewed according to Rosati's criteria and our criteria. After reclassification, the RA group was composed of 45 RAminiD and 13 RASD patients, and 26 Rosati's RA and 21 RCMD patients. All RA patients could be classified according to our criteria. However, in 10 of the RA patients, the reclassification according to Rosati's criteria is confusing because they have only two-lineage dysplasia, and one 5q− syndrome case was also excluded according to Rosati's criteria. High concordance rate (94.8%) between the two observers and high reproducibility (98.3%) by observer (AM) were found regarding our classification. All RAEB patients had trilineage dysplasia.
The analysis of the age, sex and hematological findings revealed that the RASD patients had higher blast percentage of BM cells than that of the RAminiD patients (P = 0.006), and higher erythroblast percentage of BM cells than that of the RAEB patients (P = 0.09) ( Table 1 ).
In the RAminiD group, the frequency of cytogenetic abnormalities was 7/34 (21%). In contrast, cytogenetic abnormalities were found in four (36%) of the 11 RASD patients studied and nine (75%) of the 12 RAEB patients. The frequency of cytogenetic abnormalities observed in the RASD group were intermediate between those in the RAminiD and RAEB groups. The types of cytogenetic abnormalities are summarized in Table 2 . Complex aberrations (type C in Japanese Score (JS) 10 were present in only one RAminiD patient (3%) and two RASD patients (18%). Type A abnormality in JS was present in only one RASD patient (9%) and five RAminiD patients (15%).
The frequency of disease progression to acute leukemia among the patients with RASD was lower than that among the patients with RAEB ( Table 1 ). The leukemia-free survival (LFS) time calculation revealed differences among the three groups (RAminiD vs RASD: P = 0.03, RASD vs RAEB: P = 0.04) (Figure 1 ). Only one female RAminiD patient developed acute leukemia. Although this patient was initially classified as having RAminiD because her frequency of mMgk was slightly lower than10%, we thought that her morphological findings were similar to those of RASD. She subsequently developed RASD and thereafter acute leukemia. Concerning the causes of death in our patients, the frequency of non-hematological death in the RAminiD group was higher than that in the RASD and RAEB groups. The causes of death in the RASD group were similar to those in the RAEB group (Table 3) .
Follow-up periods ranged from 2 to 203 months (median 31 months). Forty-seven of the 80 patients were still alive 2+ to 203+ months. These included 38/45 RAminiD patients, 7/13 RASD patients, and 2/22 with RAEB. The analysis of survival curves revealed differences among the three groups (RAminiD vs RASD: P = 0.06, RASD vs RAEB: p = 0.004) (Figure 2 ). Patients with RCMD had prognoses intermediate between those of the Rosati's RA and RAEB groups (Rosati's RA vs RCMD: P = 0.09, RCMD vs RAEB: P = 0.0001) (Figure 3 ).
Discussion
Gattermann et al 11 suggested that in the setting of RARS, patients with dysplastic granulocytic and/or megakaryocytic elements were at higher risk of developing acute leukemia than were those who lacked these findings. Rosati et al 5 indicated that RCMD is a distinct subset of MDS, with an unfavorable clinical outcome. We also believe that the degree of myelodysplasia reflects the prognosis in MDS patients including
Figure 1
Leukemia-free survival in RAminiD, RASD and RAEB patients. RAminiD vs RASD: P = 0.03; RASD vs RAEB: P = 0.04.
Table 3
Causes of death in RAminiD, RASD and RAEB patients Type Bleeding Infection Acute Others Total leukemia RAminiD 0 (0%) 3 (43%) 1 (14%) 3 (43%) 7 (100%) RASD 1 (17%) 3 (50%) 2 (33%) 0 (0%) 6 (100%) RAEB 1 (5%) 6 (30%) 11 (55%) 2 (10%) 20 (100%)
RAminiD, refractory anemia with minimal dysplasia; RASD, refractory anemia with severe dysplasia; RAEB, refractory anemia with excess of blasts.
those with RA. However, individual interpretation of myelodysplasia is variance. In addition, there are low frequencies of dysplasia in the BM of patients with liver disease, 12 viral infection 13 etc, and myelodysplastic features other than PseudoPelger-Huet anomalies, complete degranular neutrophils and mMgk are not able to distinguish MDS from normal subjects. 6 Aul et al 14 reported that Pseudo-Pelger-Huet anomalies and mMgk were correlated with the length of survival. Thus, we chose these two distinct dysplastic changes (Pseudo-PelgerHuet anomalies and mMgk) in part because they have specific, objective and prognostic values. In the present patients, this univariate analysis using the Kaplan-Meier method and log rank test showed that Pseudo-Pelger-Huet anomalies (P = 0.0001), mMgk (P = 0.07), Hb (P = 0.04) and BM blast (P = 0.01) were predictors of poor survival (Table 4 ). Using Cumulative survival in RAminiD, RASD and RAEB patients. RAminiD vs RASD: P = 0.06; RASD vs RAEB: P = 0.004.
proportional hazards regression multivariate analysis, the independent variables for determining outcome were PseudoPelger-Huet anomalies (P = 0.009) and Hb (P = 0.04) ( Table 5 ). These findings support Aul's previous results.
Our criteria were advantageous compared with Rosati's criteria. Firstly, our criteria were able to identify the patients with RA who were at greater risk for an unfavorable clinical course (RAminiD vs RASD: P = 0.06, Rosati's RA vs RCMD: P = 0.09). In particular, the prognostic value of our criteria in the first 3 years from the diagnosis (RAminiD vs RASD: P = 0.001) were advantageous compared with Rosati's criteria (Rosati's RA vs RCMD: P = 0.1). We think that these findings are important for decision-making regarding therapeutic strategies for RA patients. Secondly, Rosati's criteria are somewhat intricate, while our criteria are simple, more objective, and more specific for dysplasia of MDS.
In our study, the BM blast percentage, the frequency of cytogenetic abnormalities, the length of the LFS and the prognosis of the patients with RASD were intermediate between those of the RAEB and RAminiD patients. Chromosomal abnormalities associated with good prognosis predominated in the RAminiD group, whereas others associated with poor prognosis predominated in the RASD group. We believe that RASD is a distinct subset of RA with an unfavorable clinical outcome.
Figure 3
Cumulative survival in Rosati's RA, RCMD and RAEB patients. Rosati's RA vs RCMD: P = 0.09, RCMD vs RAEB: P = 0.0001.
Table 4
Univariate analysis of survival in RA patients Pelger, Pseudo-Pelger-Huet anomalies; Hb, hemoglobin; mMgk, micromegakaryocytes; PLT, platelets; ANC, absolute neutrophil count; BM, bone marrow. Abbreviations are explained in Table 4 .
